Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris
Status:
Terminated
Trial end date:
2016-03-23
Target enrollment:
Participant gender:
Summary
This study is designed as a multi-country, multicenter, open label extension to Phase III
trial OPV116910. The primary objective is to provide continued treatment with ofatumumab
subcutaneous (SC) for eligible subjects who complete the OPV116910 trial in order to obtain
further long term safety and tolerability information in subjects with pemphigus vulgaris
receiving ofatumumab SC every 4 weeks (wk).